Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

NCT02149108 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

768

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: Nintedanib (BIBF 1120)
DRUG: Placebo
DRUG: BSC
DRUG: BSC

Sponsor

Boehringer Ingelheim